Dynatronics Corporation
DYNTQ
Other OTC- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Brian D. Baker
- Full Time Employees
- 111
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1200 Trapp Road Eagan MN United States of America 55121
- IPO Date
- Jan 5, 2026
- CIK
- 0000720875
- Website
- dynatronics.com
- Similar Companies
- Business
- Dynatronics Corporation (OTC: DYNTQ) manufactures and sells advanced therapeutic and pain management products primarily for use in outpatient rehabilitation clinics, athletic training facilities, home healthcare providers, and chiropractors. The company offers a broad range of rehabilitation equipment and supplies, including electrotherapy devices such as TENS units, interferential current stimulators, muscle stimulators, iontophoresis devices, ultrasound systems, and combination therapy units; hot and cold therapy products like moist heat packs, ice packs, and cryotherapy wraps; traction devices for cervical and lumbar decompression; therapeutic exercise and range-of-motion products such as bands, tubing, weights, balance boards, and resistance equipment; treatment tables and positioning aids; and disposable supplies including electrodes, conductive gels, and patient pads. Dynatronics also provides custom-branded products under the CLIQ and other private labels, along with maintenance and repair services for its equipment. Founded in 1967 and headquartered in Eagan, Minnesota, the company operates principally in the United States, with distribution through direct sales representatives, independent distributors, and online channels targeting physical therapists, athletic trainers, and sports medicine professionals. In recent developments, Dynatronics filed for Chapter 11 bankruptcy protection in February 2024 to facilitate a court-supervised sale process amid financial challenges, culminating in its delisting from Nasdaq and trading under the DYNTQ ticker; the company completed a strategic restructuring in mid-2024, including workforce reductions and asset optimization, while securing debtor-in-possession financing to maintain operations during the proceedings; it launched new product enhancements in its Solaris Plus and SymptX brands in late 2024, focusing on wireless connectivity and AI-driven therapy protocols; and entered a distribution partnership with a major rehabilitation chain in early 2025 to expand market penetration in the Midwest region.